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Table I. Access vs number readmissions per access group
Access
Patients
(No.)
Days
1-15 16-30 31-90 Total
AVF  AVG 175 10 (3)a 24 (3) 54 (5) 88 (11)
TDC 125 11 (2) 12 (1) 49 (6) 62 (9)
aParenthesis for admissions directly related to access (ex: failure, thrombosis,
infection).
Methods: This was a retrospective analysis of 300 patients between
March 2009 and July 2010 already undergoing hemodialysis via TDC, AVF,
or AVG for readmissions at 15, 30 and 90 days.
Results: There was no statistically significant difference in the 15-, 30-,
and 90-day readmission rate in the patients with TDCs compared with
permanent access (Table I and Table II).
Conclusions: TDCs were shown to be as safe and cost-effective as
permanent access during these time periods. Shortening hospital stay by
discharging patients with TDCs and electively placing permanent access
could result in better outcomes and significant cost savings.
Table II. Negative binomial regression analysis of readmissions of TDCs
vs permanent access
Time period RR (95% CI) P
1 to 15 days 1.38 (0.56-3.37) .482
16 to 30 days 0.67 (0.33-1.35) .261
31 to 90 days 1.24 (0.81-1.91) .316
Overall 1.09 (0.75-1.58) .637
CI, Confidence interval; RR, risk ratio.
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Objective(s): Several authorities have proposed stenting of the
superior mesenteric artery (SMA)/celiac arteries (CA) as the primary
treatment for patients with chronic mesenteric ischemia. However, most
of these reports had a small sample size and short follow-up period. This
is one of the largest studies to date to analyze early and late outcomes of
stenting of SMA/CA stenosis.
Methods: During a 10-year period, 83 patients were treated and
underwent clinical follow-up and duplex ultrasound examinations to
evaluate long-term patency. A Kaplan-Meier life-table analysis was used
to estimate freedom from in-stent stenosis and late symptoms and
survival rates.
Results: Outcomes for 54 SMAs and 51 CA were analyzed. The initial
technical and clinical success rates were 97% and 96%, respectively, with 2% periop-
erative morbidity and 2% mortality. The primary late clinical success rate was 59%
and the late70% in-stent stenosis ratewas 54% at amean follow-up of 31months
(range, 1-124months).Rates for freedomfrom late recurrent symptomswere83%,
77%,70%,70%, and65%at1,2,3,4, and5years, respectively.Primarypatency rates
of the whole series were 68%, 48%, 36%, 26%, and 18% at 1, 2, 3, 4, and 5 years,
respectively, and the assisted primary patency rates were 79%, 60%, 51%, 41%, and
32%. The primary patency rates for SMA at 1, 2, 3, 4, and 5 years were 68%, 45%,
31%,24%, and16%, respectively, and theassistedprimary rateswere79%,62%,50%,
39%, and 28%. The primary patency rates for CA were 68%, 50%, 40%, 29%, and
21%, and the assisted primary rates were 79%, 58%, 52%, 42%, and 36% for 1, 2, 3,
4, and 5 years, respectively. There were no significant differences in primary or
assisted primary patency between SMA (P  .5605) or CA (P  0.5782; Fig).
Secondary intervention was done in 30% of the series.
Conclusions: Stenting of SMA/CA stenosis has a high technical and
early clinical success rates, with a satisfactory late clinical outcome;
however, it is associated with high rates of late in-stent stenosis and
intervention.
Table.
Time,
months At risk
SMA
Cum APP SE At risk
Celiac
Cum APP SE
0 51 0.9608 0.0272 54 0.9815 0.0183
1 38 0.9608 0.0272 46 0.9601 0.0277
6 33 0.9074 0.0448 39 0.8926 0.0456
12 26 0.7864 0.0684 32 0.7926 0.0621
24 19 0.6209 0.0852 19 0.5845 0.082
36 11 0.4975 0.0943 13 0.5158 0.0856
48 8 0.3918 0.0998 9 0.4232 0.0925
60 3 0.2799 0.0978 6 0.3627 0.0971
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Objective(s): This study used the a nationwide data set to identify
trends in endovascular abdomianal aortic aneurysm (AAA) repair (EVAR)
utilization and outcomes during a 5-year period.
Methods: The Nationwide Inpatient Sample database was queried
for the years 2005 to 2009. Number of EVAR cases, ratio of EVAR/open
repair (OR), major clinical outcomes, hospital costs and discharge status
were analyzed by decade. Interval data were compared with analysis of
variance and proportions via 2 tests.
Results: There were 174,714 AAA repairs (124,869 EVAR) identi-
fied. The ratio of EVAR/OR increased with increasing age. Between
2005 and 2009, the number of AAA repairs in the elderly increased by
21% (7179 vs 8554), and EVAR in patients aged 80 years increased by
50% (5057 vs 7650 P  .05). In 2009, 85% of AAA repairs in patients
aged 80 years were EVAR, and 25% of EVAR were performed in
patients aged 80 years, equivalent to age 60-69 years. The in-hospital
mortality rate remained acceptable in all age groups. EVAR-associated
mortality, length of stay, hospital costs, and discharge to skilled nursing
facility increased with each successive decade of life (P  .05). Postop-
erative myocardial infarction and acute renal failure also increased with
increasing age (P  .05). EVAR results by decade are presented in the
Table.
Conclusion: One-quarter of EVAR are performed in patients aged
80 years based on low mortality rates. There is an age-dependent
increase in death, complications, hospital costs, and discharge to ex-
tended care facilities. Such factors and long-term risk of aneurysm-related
death should be considered when evaluating the appropriateness of
elective aneurysm repair in the elderly.Fig.
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